Citizens and doctors in the town of Offagna (AN) protagonists of pilot scientific study and clinical experimentation to analyze the patient's clinical parameters in real time “AI a strategic ally of patients and doctors in fighting the pandemic” Almawave CEO Valeria Sandei says
Rome, 8 April 2021 - Almawave, a leading Italian company in Artificial Intelligence (AI), natural language analysis and Big Data services, introduces RicovAI-19, a project launched this week in the municipal territory of Offagna (AN), thanks to the collaboration between the Ancona Riuniti Hospital, Polytechnic University of the Marche, ASUR Marche and the companies Vivisol and Aditech. This is a pilot feasibility study (non-pharmacological interventional) and clinical experimentation in which Artificial Intelligence concretely supports patients, doctors and hospitals on multiple levels in the complex challenge of fighting the Covid-19 pandemic and in prospective applicability to the diagnosis and prognosis of various other diseases. The AI technologies developed for this project from Almawave allows the real-time analysis of multiple clinical parameters in users positive with Covid symptoms (body temperature, blood pressure, oxygen saturation and respiratory rate). It also allows the Clinical Stability indicators to be calculated and the results promptly sent to the doctors. The latter will remotely conduct all the subsequent assessments, make the diagnosis and prescribe any care and initiatives to manage each case. All of this takes place free of charge, thanks to a portable device used with a cell phone and a dedicated app. The instrumentation is made available to patients free of charge, thanks to the investments made by Almawave and the collaboration of the other partners. The goal of RicovAI-19, in addition to reducing Emergency Room traffic, is to rethink remote medical assistance and the territorial health care model in general.